Comparable stake leader
Cambridge Equities, LP
SEC ownership of ImmunityBio, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001326110.
Disclosed value leader
Cambridge Equities, LP
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- IBRX on Nasdaq
- Parsed ownership sources
- 13D/G, 3/4/5, and 13F
- Largest SEC-reported holder
- Cambridge Equities, LP
- Latest 13D/G holder
- Cambridge Equities, LP
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001326110
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ImmunityBio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Cambridge Equities, LP
Disclosed value leader
Cambridge Equities, LP
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 66%
13D/G row: Cambridge Equities, LP
Showing 1-8 of 50 holder rows.
Quick read
Cambridge Equities, LP leads the comparable SEC ownership view at 66%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Cambridge Equities, LP's linked filing trail.
Comparable ownership
Top 5
Cambridge Equities, LP
66%
CALIFORNIA CAPITAL EQUITY, LLC
26%
MP 13 Ventures, LLC
26%
Nant Capital, LLC
26%
BlackRock, Inc.
2.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Cambridge Equities, LP |
13D/G
3/4/5
Patrick Soon-Shiong · 10%+ Owner
|
66%
|
$4,406,356,855
745,576,456 shares
|
+$9,487,063 | 23 Feb 2026 |
| CALIFORNIA CAPITAL EQUITY, LLC |
3/4/5
10%+ Owner
|
26%
|
$571,730,825
288,752,943 shares
|
— | 31 Mar 2026 |
| MP 13 Ventures, LLC |
3/4/5
10%+ Owner
|
26%
|
$571,730,825
288,752,943 shares
|
— | 31 Mar 2026 |
| Nant Capital, LLC |
3/4/5
10%+ Owner
|
26%
|
$571,730,825
288,752,943 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
2.3%
|
$202,077,217
26,346,443 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
Company
|
1.6%
|
$135,821,150
17,708,103 shares
|
— | 31 Mar 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
1.5%
|
$125,196,213
16,322,844 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
1.3%
|
$116,029,566
15,127,714 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$2,283,602.
Buys
$0
Insiders: 0
Sells
$2,283,602
Insiders: 2
Net
-$2,283,602
Shares: -250,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 250,000
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 250,000 | $0 | $2,283,602 | -$2,283,602 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to ImmunityBio, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Patrick Soon-Shiong
Net 12M change
-$2,283,602
Latest report
31 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Patrick Soon-Shiong | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | $572,512,835 | Mixed | 31 Mar 2026 | ||
| Nant Capital, LLC | 10%+ Owner | $571,730,825 | Mixed | 31 Mar 2026 | ||
| MP 13 Ventures, LLC | 10%+ Owner | $571,730,825 | Mixed | 31 Mar 2026 | ||
| Cambridge Equities, LP | 10%+ Owner | $571,730,825 | Mixed | 31 Mar 2026 | ||
| CALIFORNIA CAPITAL EQUITY, LLC | 10%+ Owner | $571,730,825 | Mixed | 31 Mar 2026 | ||
| Barry J. Simon | Director | $16,909,279 | -$1,783,602 | -9.5% | Mixed | 24 Feb 2026 |
| Richard Adcock | CEO & President, Director | $5,917,675 | Mixed | 22 Feb 2026 | ||
| David C. Sachs | Chief Financial Officer | $2,889,293 | Mixed | 22 Feb 2026 | ||
| John C. Thomas | Former Director | $1,086,143 | Mixed | 31 Dec 2021 | ||
| Regan J. Lauer | Chief Accounting Officer | $1,035,917 | Mixed | 22 Feb 2026 | ||
| Christobel Selecky | Director | $0 | -$500,000 | -100% | Mixed | 23 Feb 2026 |
| Cheryl Cohen | Director | Mixed | 18 Jun 2025 | |||
| Linda Maxwell | Director | Mixed | 18 Jun 2025 | |||
| Bruce Wendel | Director | Mixed | 12 Dec 2025 | |||
| Wesley Clark | Director | Mixed | 18 Jun 2025 | |||
| John Owen Brennan | Director | Mixed | 11 Jun 2024 | |||
| Michael D. Blaszyk | Director | Mixed | 18 Jun 2025 |
Recent insider transactions for ImmunityBio, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Soon Shiong Patrick | IBRX | Common Stock | Conversion of derivative security | 1.87% | 4,606,596 | 251,018,873 | 31 Mar 2026 | See footnote | ||
| Soon Shiong Patrick | IBRX | Common Stock | Conversion of derivative security | 1.87% | 4,606,596 | 251,018,873 | 31 Mar 2026 | See footnote | ||
| Soon Shiong Patrick | IBRX | Common Stock | Conversion of derivative security | 1.87% | 4,606,596 | 251,018,873 | 31 Mar 2026 | See footnote | ||
| Soon Shiong Patrick | IBRX | Common Stock | Conversion of derivative security | 1.87% | 4,606,596 | 251,018,873 | 31 Mar 2026 | See footnote | ||
| Patrick Soon-Shiong | IBRX | Common Stock | Conversion of derivative security | 1.87% | 4,606,596 | 251,018,873 | 31 Mar 2026 | See footnote | ||
| Soon Shiong Patrick | IBRX | Second Amended and Restated Convertible Promissory Note | Conversion of derivative security | 0 | $480,000,000 | 31 Mar 2026 | See footnote | |||
| Soon Shiong Patrick | IBRX | Second Amended and Restated Convertible Promissory Note | Conversion of derivative security | 0 | $480,000,000 | 31 Mar 2026 | See footnote | |||
| Soon Shiong Patrick | IBRX | Second Amended and Restated Convertible Promissory Note | Conversion of derivative security | 0 | $480,000,000 | 31 Mar 2026 | See footnote | |||
| Soon Shiong Patrick | IBRX | Second Amended and Restated Convertible Promissory Note | Conversion of derivative security | 0 | $480,000,000 | 31 Mar 2026 | See footnote | |||
| Patrick Soon-Shiong | IBRX | Second Amended and Restated Convertible Promissory Note | Conversion of derivative security | 0 | $480,000,000 | 31 Mar 2026 | See footnote | |||
| Barry J. Simon | IBRX | Common Stock | Sale | -2.56% | -75,000 | 2,850,821 | 24 Feb 2026 | Direct | ||
| Christobel Selecky | IBRX | Common Stock | Sale | -100% | $250,000 | $10.00 | -25,000 | 0 | 23 Feb 2026 | Direct |
| Christobel Selecky | IBRX | Common Stock | Options Exercise | 25,000 | 25,000 | 23 Feb 2026 | Direct | |||
| Christobel Selecky | IBRX | Stock Option (right to buy) | Options Exercise | -26.9% | -25,000 | 67,937 | 23 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Common Stock | Sale | -5.34% | $1,691,102 | $10.25 | -165,000 | 2,925,821 | 23 Feb 2026 | Direct |
| David C. Sachs | IBRX | Common Stock | Tax liability | -6.45% | -20,682 | 300,143 | 22 Feb 2026 | Direct | ||
| David C. Sachs | IBRX | Common Stock | Options Exercise | 14.5% | 40,650 | 320,825 | 22 Feb 2026 | Direct | ||
| David C. Sachs | IBRX | Restricted Stock Units | Options Exercise | -50% | -40,650 | 40,651 | 22 Feb 2026 | Direct | ||
| Patrick Soon-Shiong | IBRX | Common Stock | Tax liability | -0.2% | -58,170 | 29,757,911 | 22 Feb 2026 | Direct | ||
| Patrick Soon-Shiong | IBRX | Common Stock | Options Exercise | 0.38% | 114,329 | 29,816,081 | 22 Feb 2026 | Direct | ||
| Patrick Soon-Shiong | IBRX | Restricted Stock Units | Options Exercise | -50% | -114,329 | 114,329 | 22 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Common Stock | Tax liability | -1.42% | -1,673 | 115,875 | 22 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Common Stock | Options Exercise | 3.58% | 4,065 | 117,548 | 22 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Restricted Stock Units | Options Exercise | -50% | -4,065 | 4,065 | 22 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Common Stock | Tax liability | -12.2% | -77,560 | 560,344 | 22 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Common Stock | Options Exercise | 31.4% | 152,439 | 637,904 | 22 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Restricted Stock Units | Options Exercise | -50% | -152,439 | 152,439 | 22 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Common Stock | Tax liability | -0.19% | -6,026 | 3,090,821 | 22 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Common Stock | Options Exercise | 0.49% | 15,243 | 3,096,847 | 22 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Restricted Stock Units | Options Exercise | -50% | -15,243 | 15,245 | 22 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Common Stock | Sale | -0.32% | $92,500 | $9.25 | -10,000 | 3,081,604 | 20 Feb 2026 | Direct |
| Patrick Soon-Shiong | IBRX | Common Stock | Tax liability | -0.4% | -118,560 | 29,701,752 | 10 Feb 2026 | Direct | ||
| Patrick Soon-Shiong | IBRX | Common Stock | Options Exercise | 0.93% | 274,122 | 29,820,312 | 10 Feb 2026 | Direct | ||
| Patrick Soon-Shiong | IBRX | Restricted Stock Units | Options Exercise | -33.3% | -274,122 | 548,246 | 10 Feb 2026 | Direct | ||
| David C. Sachs | IBRX | Common Stock | Tax liability | -13.2% | -42,643 | 280,175 | 10 Feb 2026 | Direct | ||
| David C. Sachs | IBRX | Common Stock | Options Exercise | 34.2% | 82,236 | 322,818 | 10 Feb 2026 | Direct | ||
| David C. Sachs | IBRX | Restricted Stock Units | Options Exercise | -33.3% | -82,236 | 164,474 | 10 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Common Stock | Tax liability | -1.95% | -2,257 | 113,483 | 10 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Common Stock | Options Exercise | 4.97% | 5,482 | 115,740 | 10 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Restricted Stock Units | Options Exercise | -33.3% | -5,482 | 10,965 | 10 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Common Stock | Tax liability | -22.4% | -140,048 | 485,465 | 10 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Common Stock | Options Exercise | 78% | 274,122 | 625,513 | 10 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Restricted Stock Units | Options Exercise | -33.3% | -274,122 | 548,246 | 10 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Common Stock | Sale | -4.69% | -151,967 | 3,091,604 | 20 Jan 2026 | Direct | ||
| Christobel Selecky | IBRX | Common Stock | Sale | -100% | -25,000 | 0 | 20 Jan 2026 | Direct | ||
| Christobel Selecky | IBRX | Common Stock | Options Exercise | 25,000 | 25,000 | 20 Jan 2026 | Direct | |||
| Christobel Selecky | IBRX | Stock Option (right to buy) | Options Exercise | -21.2% | -25,000 | 92,937 | 20 Jan 2026 | Direct | ||
| Christobel Selecky | IBRX | Common Stock | Sale | -100% | $250,000 | $5.00 | -50,000 | 0 | 16 Jan 2026 | Direct |
| Christobel Selecky | IBRX | Common Stock | Options Exercise | 50,000 | 50,000 | 16 Jan 2026 | Direct | |||
| Christobel Selecky | IBRX | Stock Option (right to buy) | Options Exercise | -29.8% | -50,000 | 117,937 | 16 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.